Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN D MODENA

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1235379207
CMS profile
237625
Location
LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$21,124.57

174 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN D MODENA

NPI 1235379207 · CMS profile ID 237625

Allopathic & Osteopathic Physicians / Allergy & Immunology

LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235379207?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN D MODENA, NPI 1235379207, CMS profile ID 237625. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235379207?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BRIAN D MODENA, NPI 1235379207, CMS profile ID 237625. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235379207?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BRIAN D MODENA, NPI 1235379207, CMS profile ID 237625, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1235379207?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

174 matching records · $21,124.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 174 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 174.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharming Healthcare, Inc. $26.5905/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200800939 CMS
Regeneron Healthcare Solutions, Inc. $16.2805/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212992406 CMS
GlaxoSmithKline, LLC. $26.6105/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191015406 CMS
GENZYME CORPORATION $42.2505/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233433979 CMS
ARS Pharmaceuticals Operations, Inc. $25.0405/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245885187 CMS
Takeda Pharmaceuticals U.S.A., Inc. $31.7705/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223927418 CMS
Amgen Inc. $71.5505/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228294408 CMS
Amgen Inc. $23.4305/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228294404 CMS
CSL Behring $32.5705/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232368480 CMS
Incyte Corporation $18.2405/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226111931 CMS
Lilly USA, LLC $29.1205/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186547462 CMS
ARS Pharmaceuticals Operations, Inc. $18.3405/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245885185 CMS
Novartis Pharmaceuticals Corporation $23.3105/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200704791 CMS
Novartis Pharmaceuticals Corporation $0.1605/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200704793 CMS
GENZYME CORPORATION $46.4404/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233433981 CMS
Siemens Medical Solutions USA, Inc. $21.6004/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211438353 CMS
Blueprint Medicines Corporation $31.8204/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235822241 CMS
Electromed, Inc. $18.1604/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224606500 CMS
Amgen Inc. $6.0004/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227094417 CMS
GlaxoSmithKline, LLC. $34.5004/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191393311 CMS
PFIZER INC. $19.1504/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231475407 CMS
Incyte Corporation $20.3804/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226100522 CMS
Novartis Pharmaceuticals Corporation $27.2304/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200704787 CMS
Novartis Pharmaceuticals Corporation $0.1704/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200704789 CMS
AstraZeneca Pharmaceuticals LP $15.6704/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206555295 CMS
CSL Behring $15.7104/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232368466 CMS
SANOFI-AVENTIS U.S. LLC $9,522.0004/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233434015 CMS
SANOFI-AVENTIS U.S. LLC $76.0004/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233434017 CMS
X4 Pharmaceuticals, Inc. $41.8404/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253113055 CMS
Regeneron Healthcare Solutions, Inc. $38.9303/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212992404 CMS
GlaxoSmithKline, LLC. $17.9403/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190358594 CMS
GlaxoSmithKline, LLC. $30.8403/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191714339 CMS
AstraZeneca Pharmaceuticals LP $1,074.0003/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1207019562 CMS
Grifols USA, LLC $23.2103/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249568693 CMS
GlaxoSmithKline, LLC. $30.5203/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190601011 CMS
ARS Pharmaceuticals Operations, Inc. $25.9603/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245885183 CMS
AstraZeneca Pharmaceuticals LP $17.3003/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206675398 CMS
Blueprint Medicines Corporation $2,551.2503/14/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1235822299 CMS
Regeneron Healthcare Solutions, Inc. $25.7903/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212992402 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.8903/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223916435 CMS
Cycle Pharmaceuticals Inc $15.3103/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248900683 CMS
LEO Pharma Inc. $0.7303/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252023801 CMS
LEO Pharma Inc. $29.1403/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252023803 CMS
Amgen Inc. $114.4003/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228294402 CMS
Amgen Inc. $39.5402/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228294412 CMS
Amgen Inc. $36.1002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228294406 CMS
Blueprint Medicines Corporation $74.0902/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235822297 CMS
GENZYME CORPORATION $3,420.0002/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1233433987 CMS
Lilly USA, LLC $22.0602/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186538207 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.1802/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223908885 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73,780.43 115
PY2020 $72,862.11 63
PY2021 $93,944.18 95
PY2022 $119,278.50 180
PY2023 $53,071.70 173
PY2024 $19,150.51 197
PY2025 $21,124.57 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,778.32 7
PY2025 Principal investigator $737,587.24 89
PY2024 Principal investigator $240,924.19 371
PY2023 Recipient $1,250.00 3
PY2023 Principal investigator $91,240.33 47
PY2022 Recipient $3,000.00 8
PY2022 Principal investigator $41,561.64 5
PY2021 Recipient $3,940.75 3
PY2021 Principal investigator $116,702.28 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

96 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $13,365.21 12/24/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192186976
Principal investigator 1 GlaxoSmithKline, LLC. $4,083.60 12/24/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192188357
Principal investigator 1 SANOFI US SERVICES INC. $5,018.40 12/22/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study No dispute reported 06/30/2026 1226121840
Principal investigator 1 SANOFI US SERVICES INC. $1,997.00 12/22/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226121848
Principal investigator 1 SANOFI US SERVICES INC. $4,785.00 12/22/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226121852
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,260.00 12/18/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244050732
Principal investigator 1 SANOFI US SERVICES INC. $150.00 12/12/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226101671
Principal investigator 1 SANOFI US SERVICES INC. $15,588.85 12/12/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226101677
Principal investigator 1 SANOFI US SERVICES INC. $150.00 12/12/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226101695
Principal investigator 1 SANOFI US SERVICES INC. $10,265.15 12/12/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226101702
Principal investigator 1 GlaxoSmithKline, LLC. $2,160.04 12/11/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192186990
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,800.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266525
Principal investigator 1 GlaxoSmithKline, LLC. $20,299.00 11/24/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE TH No dispute reported 06/30/2026 1192186981
Principal investigator 1 SANOFI US SERVICES INC. $926.10 11/17/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study No dispute reported 06/30/2026 1226121818
Principal investigator 1 SANOFI US SERVICES INC. $5,655.00 11/10/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226121802
Principal investigator 1 SANOFI US SERVICES INC. $6,225.00 11/10/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226121809
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 11/07/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226101708
Principal investigator 1 SANOFI US SERVICES INC. $1,150.00 11/04/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study No dispute reported 06/30/2026 1226121814
Principal investigator 1 SANOFI US SERVICES INC. $4,572.00 11/04/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226121821
Principal investigator 1 SANOFI US SERVICES INC. $15,646.00 10/27/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226121793
Principal investigator 1 SANOFI US SERVICES INC. $5,161.00 10/27/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226121797
Principal investigator 1 SANOFI US SERVICES INC. $7,020.00 10/20/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226121779
Principal investigator 1 SANOFI US SERVICES INC. $8,320.80 10/20/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226121789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,085.21 10/17/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251293
Principal investigator 1 SANOFI US SERVICES INC. $28,250.00 10/15/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226101595
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 10/15/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226101615
Principal investigator 1 SANOFI US SERVICES INC. $3,460.00 10/14/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226121760
Principal investigator 1 SANOFI US SERVICES INC. $400.00 10/14/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study No dispute reported 06/30/2026 1226121763
Principal investigator 1 SANOFI US SERVICES INC. $38,196.05 10/14/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121769
Principal investigator 1 SANOFI US SERVICES INC. $18,900.00 10/14/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121772
Principal investigator 1 SANOFI US SERVICES INC. $926.10 10/14/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study No dispute reported 06/30/2026 1226121776
Principal investigator 1 SANOFI US SERVICES INC. $11,674.00 10/06/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226121755
Principal investigator 1 GlaxoSmithKline, LLC. $6,821.17 09/18/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192188349
Principal investigator 1 SANOFI US SERVICES INC. $16,445.00 09/08/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226121744
Principal investigator 1 SANOFI US SERVICES INC. $3,881.70 09/03/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study No dispute reported 06/30/2026 1226121742
Principal investigator 1 SANOFI US SERVICES INC. $28,184.00 08/25/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226121512
Principal investigator 1 SANOFI US SERVICES INC. $7,800.00 08/25/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226121739
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 08/18/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226121508
Principal investigator 1 SANOFI US SERVICES INC. $926.10 08/11/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study No dispute reported 06/30/2026 1226121498
Principal investigator 1 SANOFI US SERVICES INC. $26,690.00 08/11/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226121504
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 07/28/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226121491
Principal investigator 1 GlaxoSmithKline, LLC. $31,851.60 07/22/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192188345
Principal investigator 1 SANOFI US SERVICES INC. $24,214.00 07/21/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226121469
Principal investigator 1 SANOFI US SERVICES INC. $8,420.80 07/21/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226121482
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 07/21/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226121487
Principal investigator 1 Blueprint Medicines Corporation $27,677.50 07/16/2025 Non-covered Recipient Entity
Modena Allergy & Asthma Clinical Research - La Jolla
BLU-808-1201 No dispute reported 06/30/2026 1235785607
Principal investigator 1 SANOFI US SERVICES INC. $37,830.00 07/14/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226121479
Principal investigator 1 SANOFI US SERVICES INC. $3,341.70 07/07/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study No dispute reported 06/30/2026 1226121463
Principal investigator 1 SANOFI US SERVICES INC. $7,766.19 07/02/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226121474
Principal investigator 1 GlaxoSmithKline, LLC. $2,164.14 05/22/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192188353
Principal investigator 1 SANOFI US SERVICES INC. $24,656.48 05/05/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226121454
Principal investigator 1 GlaxoSmithKline, LLC. $25,217.62 04/24/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192186994
Principal investigator 1 SANOFI US SERVICES INC. $24,062.00 04/21/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study No dispute reported 06/30/2026 1226121460
Recipient SANOFI US SERVICES INC. $1,553.35 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226123122
Recipient SANOFI US SERVICES INC. $395.38 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226123125
Recipient SANOFI US SERVICES INC. $395.50 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226123127
Recipient SANOFI US SERVICES INC. $81.75 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226123132
Recipient SANOFI US SERVICES INC. $79.03 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226123136
Recipient SANOFI US SERVICES INC. $43.60 04/04/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226123140
Recipient SANOFI US SERVICES INC. $229.71 04/03/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226123130
Principal investigator 1 SANOFI US SERVICES INC. $24,100.00 03/24/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226121426
Principal investigator 1 SANOFI US SERVICES INC. $24,100.00 03/04/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1226121445
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/28/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244050838
Principal investigator 1 AstraZeneca Pharmaceuticals LP $35,030.51 02/26/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A Multicentre,Randomised,Double Blind,Parallel Group,Placebo Controlled,52 week,Phase 3,Efficacy and Safety Study of Tezepelumab in 5 to 12 Year Old Children with Severe Uncontrolled Asthma HORIZON No dispute reported 06/30/2026 1185542860
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $21,000.00 02/13/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244050730
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $409.20 02/12/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244050836
Principal investigator 1 GlaxoSmithKline, LLC. $8,226.71 01/30/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192186984
Principal investigator 1 Amgen Inc. $26,511.90 01/27/2025 Non-covered Recipient Entity
ORSO HEALTH INC
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246646156
Principal investigator 1 SANOFI US SERVICES INC. $6,481.83 01/21/2025 Non-covered Recipient Entity
Brian D Modena Orso Health Inc
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226121429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 01/16/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,700.00 01/16/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 01/16/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/16/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,800.00 01/16/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 01/16/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 01/16/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,999.00 01/16/2025 Non-covered Recipient Entity
ORSO HEALTH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $702.04 01/02/2025 Non-covered Recipient Entity
MODENA ALLERGY AND ASTHMA INC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144354
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $702.04 01/02/2025 Non-covered Recipient Entity
MODENA ALLERGY AND ASTHMA INC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $702.04 01/02/2025 Non-covered Recipient Entity
MODENA ALLERGY AND ASTHMA INC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144358
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $702.04 01/02/2025 Non-covered Recipient Entity
MODENA ALLERGY AND ASTHMA INC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144360
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.41 01/02/2025 Non-covered Recipient Entity
MODENA ALLERGY AND ASTHMA INC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144362
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.41 01/02/2025 Non-covered Recipient Entity
MODENA ALLERGY AND ASTHMA INC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144364